Expression of β-catenin protein in hepatocellular carcinoma and its relationship with alpha-fetoprotein

Abstract

This study aimed to investigate the expression of β-catenin in hepatocellular carcinoma (HCC) tissues and its relationship with α-fetoprotein (AFP) in HCC. Immunohistochemistry was used to determine the expression of β-catenin in normal liver tissues (n=10), liver cirrhosis tissues (n=20), and primary HCC tissues (n=60). The relationship between β-catenin expression and clinical parameters of HCC was investigated. Real-time PCR and Western blotting were used to detect the mRNA and protein expression levels of β-catenin in the liver cancer cell line SMMC-7721 transfected with a plasmid encoding AFP, and also the mRNA and protein expression levels of β-catenin were measured in the liver cancer cell line Huh7 before and after the transfection with AFP shRNA plasmids. The results showed that β-catenin was only expressed on the cell membrane in normal liver tissues. Its localization to the cytoplasm and nucleus of cells was observed in a small proportion of cirrhotic tissues or adjacent HCC tissues, and such ectopic expression of β-catenin was predominant in HCC tissues. The abnormal expression of β-catenin was correlated with serum AFP levels, cancer cell differentiation and vascular invasion (P<0.05). Additionally, the increased expression of AFP resulted in the upregulation of β-catenin mRNA and protein levels, while knockdown of AFP with AFP shRNA led to significantly decreased β-catenin mRNA and protein levels (P<0.05). It was suggested that the abnormal expression of β-catenin is implicated in hepatic carcinogenesis and development. AFP can lead to increased expression of β-catenin, which may account for the poor prognosis of AFP-associated HCC patients.

Keywords

β-catenin / hepatocellular carcinoma / α-fetoprotein

References

[1] ZhangX, HaoJ. Development of anticancer agents targeting the Wnt/beta-catenin signaling. Am J Cancer Res, 2015, 5(8): 2344-2360 PMID: 26396911 PMCID: 4568771

[2] DahmaniR, JustPA, PerretC. The Wnt/beta-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol, 2011, 35(11): 709-713 PMID: 21778132

[3] NovellasdemuntL, AntasP, LiVS. Targeting Wnt signaling in colorectal cancer. A review in the theme: cell signaling: proteins, pathways and mechanisms. Am J Physiol Cell Physiol, 2015, 309(8): C511-C521 PMID: 26289750

[4] KingTD, SutoMJ, LiY. The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem, 2012, 113(1): 13-18 PMID: 21898546

[5] ChenH, ChaiW, LiB, et al. . Effects of ß-catenin on differentially expressed genes in multiple myeloma. J Huazhong Univ Sci Technol[Med Sci], 2015, 35(4): 546-552

[6] BaoZQ, ZhangCC, XiaoYZ, et al. . Over-expreßsion of Sox4 and ß-catenin is associated with a less favorable prognosis of osteosarcoma. J Huazhong Univ Sci Technol[ Med Sci], 2016, 36(2): 193-199

[7] WaidelyE, Al-YuobiAR, BashammakhAS, et al. . Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst, 2016, 141(1): 36-44 PMID: 26606739

[8] ChunS, RhieSY, KiCS, et al. . Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas. Ann Hepatol, 2015, 14(6): 882-888 PMID: 26436360

[9] YouJ, YangH, LaiY, et al. . ARID2, p110alpha, p53, and beta-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications. Hum Pathol, 2015, 46(7): 1068-1077 PMID: 26284269

[10] JamiesonC, SharmaM, HendersonBR. Targeting the beta-catenin nuclear transport pathway in cancer. Semin Cancer Biol, 2014, 27: 20-29 PMID: 24820952

[11] WangLY, LiB, JiangHH, et al. . Inhibition effect of miR-577 on hepatocellular carcinoma cell growth via targeting beta-catenin. Asian Pac J Trop Med, 2015, 8(11): 923-929 PMID: 26614992

[12] HuiHY, WuN, WuM, et al. . Dihydroartemisinin suppresses growth of squamous cell carcinoma A431 cells by targeting the Wnt/beta-catenin pathway. Anticancer Drugs, 2016, 27(2): 99-105 PMID: 26457547

[13] LiuL, YuXJ, WuCT, et al. . Reduction of ß-catenin expression in hepatocellular carcinoma inhibited the enhanced metastatic potential of hypoxia. Chin J Hepatobil Surg, 2012, 18(1): 58-62

[14] BellissimoF, PinzoneMR, CacopardoB, et al. . Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol, 2015, 21(42): 12003-12021 PMID: 26576088 PMCID: 4641121

[15] LiMS, LiPF, HeSP, et al. . The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line. World J Gastroenterol, 2002, 8(3): 469-475 PMID: 12046072 PMCID: 4656423

[16] LiM, ZhuM, LiW, et al. . Alpha-fetoprotein receptor as an early indicator of HBx-driven hepatocarcinogenesis and its applications in tracing cancer cell metastasis. Cancer Lett, 2013, 330(2): 170-180 PMID: 23211536

[17] LiMS, LiPF, ChenQ, et al. . Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. World J Gastroenterol, 2004, 10(6): 819-824 PMID: 15040024 PMCID: 4726995